Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Phase 1 on
ClassNone selected

Phase 1 included.

Clear filters

15 of 15 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

alkylating chemotherapy 2

Registry, Oct 31, 2029
Registry, Dec 31, 2026

ATR inhibitor (ATRX-altered) 1

TuvusertibPhase 2
Registry, Sep 2028

DNMT inhibitor 1

Registry, Jan 2027

mutant IDH1 inhibitor 3

FDA Fast Track granted, Aug 20, 2026Registry, Dec 2028
Registry, Jun 2029
IvosidenibPhase 1
No dated milestone in 2025 to 2030

mutant IDH1/IDH2 inhibitor 2

VorasidenibApproved
SNO 2026: INDIGO 41.6-month, seizure/QoL, real-world grade 2 and 3, Nov 12, 2026Registry, Aug 2027
Registry, Dec 2026

PARP inhibitor 3

OlaparibPhase 2
Registry, Jan 2027
No dated milestone in 2025 to 2030
NiraparibPhase 1
No dated milestone in 2025 to 2030

PD-1 antibody 1

NivolumabPhase 2
No dated milestone in 2025 to 2030

peptide vaccine 1

Registry, Dec 31, 2032

retinoid plus PD-1 antibody 1

Registry, Jun 2027